Home / NEWS / Top News / Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years

Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years

Biogen CEO Michel Vounatsos told CNBC that the muster price of $56,000 per year for the company’s FDA-approved Alzheimer’s disease drug aducanumab is “fair.”

Check Also

Ponzi schemer Madoff earned $710 for almost 3,000 hours of prison work, got ‘not very dependable’ review

Bernie Madoff decreased in prison, where he was serving a 150-year sentence for running the …

Leave a Reply

Your email address will not be published. Required fields are marked *